Liquid Botulinum Toxin Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current botulinum toxin formulations, particularly in liquid form, face challenges with stability during storage and transport, leading to potential loss of biological activity due to heat, light, and surface denaturation.
Innovation Solution
A liquid botulinum toxin formulation comprising botulinum toxin, human serum albumin (HSA) as a stabilizing protein, and a chelating agent such as EDTA or phosphate, which enhances heat and light stability, and optionally includes salts of calcium, magnesium, or zinc to reduce injection pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If botulinum toxin is formulated as a liquid solution for convenient administration, then ease of operation is improved, but stability during storage and transport deteriorates due to heat, light, and surface denaturation
Solution Approach 1:
The patent introduces a stabilizing protein (such as human serum albumin, ovalbumin, or casein) as an intermediary substance that binds to botulinum toxin and protects it from denaturation. This mediator prevents direct contact between the toxin and harmful environmental factors (heat, light, surface), thereby maintaining stability in liquid formulation without sacrificing ease of administration
Solution Approach 2:
The patent modifies the formulation parameters by adding specific stabilizing proteins and chelating agents to the liquid solution. These parameter changes (adding protective substances) enable the liquid formulation to maintain stability against heat, light, and surface denaturation while preserving the convenience of liquid administration
2Quantity of substance
If botulinum toxin is formulated at extremely high potency (1 ng per vial) to achieve therapeutic effect, then therapeutic efficacy is improved, but loss of toxin activity due to surface denaturation increases
Solution Approach 1:
The stabilizing protein acts as a protective intermediary that surrounds and shields the highly potent toxin molecules. This mediator prevents surface denaturation of the toxin, ensuring that even at extremely high potency concentrations (1 ng per vial), the toxin activity is retained and therapeutic efficacy is maintained
3Stability of the object's composition
If lyophilized powder form is used for long-term storage stability, then stability during storage is improved, but ease of operation deteriorates due to reconstitution requirements and potential dosing errors
Solution Approach 1:
The patent changes the physical state parameter of the formulation from solid (lyophilized powder) to liquid (ready-to-use solution). This parameter change eliminates the need for reconstitution, reducing dosing errors and simplifying administration, while the added stabilizing proteins and chelating agents maintain storage stability in the liquid form
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved stability against heat and light, reducing potential activity loss and simplifying storage and handling, while also providing reduced injection pain with the addition of certain salts.
Implementation Method 1
a stabilizing protein such as human serum albumin
Implementation Method 2
improved formulation that is both heat and light stable
Implementation Method 3
improved formulation that is both heat and light stable
Implementation Method 4
a chelating agent (e.g., EDTA) or phosphate
Implementation Method 5
a chelating agent such as EDTA or phosphate, which enhances heat and light stability
Implementation Method 6
a salt of calcium, magnesium or zinc, or a mixture thereof... providing reduced injection pain
Data Source
AI summary
The present invention relates to a liquid botulinum toxin formulation comprising: (i) botulinum toxin, (ii) a stabilizing protein such as human serum albumin, (iii) a chelating agent (e.g., EDTA) or phosphate, and optionally (iv) a salt of calcium, magnesium or zinc, (v) a tonicity agent and/or (vi) a buffering agent. In addition, the present invention relates to the use of the liquid botulinum toxin formulation for therapeutic and cosmetic treatments.